AIMS: To evaluate pulmonary deposition and gas exchange following nebulisation of two surfactants by either a jet or an ultrasonic nebuliser. METHOD: After bronchoalveolar lavage (BAL), 19 rabbits were ventilated in four groups. Group A1 (n = 5) and A2 (n = 6) received Technetium-99m labelled Exosurf, and groups B1 (n = 4) and B2 (n = 4) received radiolabelled Survanta. Groups A1 and B1 received jet nebuliser therapy, whereas groups A2 and B2 received ultrasonic nebuliser. Pulmonary deposition, distribution, and blood gases were determined. RESULTS: Pulmonary deposition as per cent of initial dose and mg lipid) was 0.28(0.10)% or 0.59(0.21) mg in group A1, 1.05(0.23)% or 2.21(0.48) mg in group A2, 0.08(0.02)% or 0.30(0.08) mg in group B1, and 0.09(0.02)% or 0.34(0.08) mg in group B2. Deposition in group A2 was greater than in other groups (p = 0.001). Group A2 showed a small improvement in blood gases. CONCLUSIONS: Even the highest deposition--ultrasonic nebuliser with Exosurf--achieved limited clinical effect. The aerosol route is currently not effective for surfactant treatment.
AIMS: To evaluate pulmonary deposition and gas exchange following nebulisation of two surfactants by either a jet or an ultrasonic nebuliser. METHOD: After bronchoalveolar lavage (BAL), 19 rabbits were ventilated in four groups. Group A1 (n = 5) and A2 (n = 6) received Technetium-99m labelled Exosurf, and groups B1 (n = 4) and B2 (n = 4) received radiolabelled Survanta. Groups A1 and B1 received jet nebuliser therapy, whereas groups A2 and B2 received ultrasonic nebuliser. Pulmonary deposition, distribution, and blood gases were determined. RESULTS: Pulmonary deposition as per cent of initial dose and mg lipid) was 0.28(0.10)% or 0.59(0.21) mg in group A1, 1.05(0.23)% or 2.21(0.48) mg in group A2, 0.08(0.02)% or 0.30(0.08) mg in group B1, and 0.09(0.02)% or 0.34(0.08) mg in group B2. Deposition in group A2 was greater than in other groups (p = 0.001). Group A2 showed a small improvement in blood gases. CONCLUSIONS: Even the highest deposition--ultrasonic nebuliser with Exosurf--achieved limited clinical effect. The aerosol route is currently not effective for surfactant treatment.
Authors: R G Spragg; N Gilliard; P Richman; R M Smith; R D Hite; D Pappert; B Robertson; T Curstedt; D Strayer Journal: Chest Date: 1994-01 Impact factor: 9.410
Authors: J van der Bleek; F B Plötz; F M van Overbeek; A Heikamp; H Beekhuis; R H Wildevuur; A Okken; S Bambang Oetomo Journal: Pediatr Res Date: 1993-08 Impact factor: 3.756
Authors: J G Weg; R A Balk; R S Tharratt; S G Jenkinson; J B Shah; D Zaccardelli; J Horton; E N Pattishall Journal: JAMA Date: 1994-11-09 Impact factor: 56.272
Authors: H Segerer; W van Gelder; F W Angenent; L J van Woerkens; T Curstedt; M Obladen; B Lachmann Journal: Pediatr Res Date: 1993-10 Impact factor: 3.756
Authors: A Anzueto; R P Baughman; K K Guntupalli; J G Weg; H P Wiedemann; A A Raventós; F Lemaire; W Long; D S Zaccardelli; E N Pattishall Journal: N Engl J Med Date: 1996-05-30 Impact factor: 91.245
Authors: Ilaria Milesi; David G Tingay; Emanuela Zannin; Federico Bianco; Paolo Tagliabue; Fabio Mosca; Anna Lavizzari; Maria Luisa Ventura; C Elroy Zonneveld; Elizabeth J Perkins; Don Black; Magdy Sourial; Raffaele L Dellacá Journal: Pediatr Res Date: 2016-03-08 Impact factor: 3.756
Authors: Carmen Rey-Santano; Victoria E Mielgo; Miguel Angel Gomez-Solaetxe; Federico Bianco; Fabrizio Salomone; Begoña Loureiro Journal: Crit Care Med Date: 2020-06 Impact factor: 7.598
Authors: Robert M DiBlasi; Masaki Kajimoto; Jonathan A Poli; Gail Deutsch; Juergen Pfeiffer; Joseph Zimmerman; David N Crotwell; Patrik Malone; James B Fink; Coral Ringer; Rajesh Uthamanthil; Dolena Ledee; Michael A Portman Journal: Crit Care Explor Date: 2021-02-15